1-4 of 4
Qing Huang
Close
Sort by
Journal Articles

Real-World Persistence and Time to Next Treatment with Ibrutinib Treatment in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke

Anna Narezkina, Xiaoxiao Lu, Bruno Emond, Aurélie Côté-Sergent, Annalise Hilts, Stephanie Liu, Marie-Hélène Lafeuille, Patrick Lefebvre, Qing Huang
Journal: Blood
Blood (2021) 138 (Supplement 1): 4112.
https://doi.org/10.1182/blood-2021-148640
Published: 2021
Journal Articles

Clinical and Economic Burden of Tumor Lysis Syndrome Among Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Kerry Rogers, Bruno Emond, Aurélie Côté-Sergent, Frédéric Kinkead, Marie-Hélène Lafeuille, Patrick Lefebvre, Qing Huang
Journal: Blood
Blood (2021) 138 (Supplement 1): 4030.
https://doi.org/10.1182/blood-2021-148575
Published: 2021
Journal Articles

Clinical Outcomes Among Real-World Patients with Chronic Lymphocytic Leukemia (CLL) Initiating First-Line Ibrutinib or Chemoimmunotherapy (CIT) Stratified By Risk Status: Results from a US Retrospective Chart Review Study

Qing Huang, PhD, Kathleen L Deering, Qing Harshaw, MD PhD, Tarun Bhagnani, MS, Lori A. Leslie, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 16–18.
https://doi.org/10.1182/blood-2020-136121
Published: 2020
Journal Articles

Real-World Prognostic Biomarker Testing, Treatment Patterns and Dosing Among 1461 Patients (pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) from the informCLL Prospective Observational Registry

Anthony R. Mato, MD, Jacqueline C. Barrientos, MD, Jeff P Sharman, MD, Danielle M. Brander, MD, Meghan Gutierrez, BA, Karen Kadish, MSN, Israel Arango-Hisijara, MD, Sandhya Upasani, Jennifer Han, PharmD, MBA, Qing Huang, PhD, Reethi Iyengar, PhD, Nilanjan Ghosh, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 42–43.
https://doi.org/10.1182/blood-2020-133798
Published: 2020